Dominick J. Angiolillo focuses on Clopidogrel, Internal medicine, Cardiology, Aspirin and Percutaneous coronary intervention. His research integrates issues of Platelet activation, Platelet and Anesthesia in his study of Clopidogrel. Dominick J. Angiolillo has researched Internal medicine in several fields, including Diabetes mellitus and Endocrinology.
Dominick J. Angiolillo combines subjects such as Stroke, Thrombosis, Randomized controlled trial and Stent with his study of Cardiology. His studies deal with areas such as Regimen, Pharmacotherapy, Antithrombotic and Clinical trial as well as Aspirin. His studies examine the connections between Percutaneous coronary intervention and genetics, as well as such issues in Conventional PCI, with regards to Pharmacodynamics.
His scientific interests lie mostly in Internal medicine, Cardiology, Clopidogrel, Percutaneous coronary intervention and Aspirin. His study in Coronary artery disease, Acute coronary syndrome, Myocardial infarction, Ticagrelor and Platelet is done as part of Internal medicine. His studies in Cardiology integrate themes in fields like Diabetes mellitus and Thrombosis, Surgery.
His research investigates the connection with Clopidogrel and areas like Platelet aggregation inhibitor which intersect with concerns in Ticlopidine. His work carried out in the field of Percutaneous coronary intervention brings together such families of science as Angioplasty, Randomized controlled trial, Conventional PCI and Intensive care medicine. His Aspirin study combines topics in areas such as Gastroenterology and Clinical trial.
Dominick J. Angiolillo mainly investigates Internal medicine, Cardiology, Percutaneous coronary intervention, Ticagrelor and Aspirin. His work on Myocardial infarction, Acute coronary syndrome, Clopidogrel and P2Y12 as part of general Internal medicine study is frequently linked to In patient, therefore connecting diverse disciplines of science. Clopidogrel is closely attributed to CYP2C19 in his study.
His Percutaneous coronary intervention study integrates concerns from other disciplines, such as Conventional PCI, Antithrombotic, Stent and Clinical endpoint, Randomized controlled trial. His Ticagrelor research includes themes of Diabetes mellitus, Pharmacodynamics, Prasugrel and Hazard ratio. The various areas that Dominick J. Angiolillo examines in his Aspirin study include Platelet and Pharmacology.
His main research concerns Internal medicine, Percutaneous coronary intervention, Ticagrelor, Myocardial infarction and Cardiology. His study in Clopidogrel, Acute coronary syndrome, Aspirin, Stroke and P2Y12 is carried out as part of his studies in Internal medicine. Dominick J. Angiolillo has included themes like CYP2C19 and Coagulation in his Clopidogrel study.
His Percutaneous coronary intervention research includes elements of Platelet aggregation inhibitor, Clinical trial, Conventional PCI, Antithrombotic and Coronary artery disease. He combines subjects such as Platelet activation, Placebo, Clinical endpoint and Kidney disease with his study of Myocardial infarction. Dominick J. Angiolillo works mostly in the field of Cardiology, limiting it down to concerns involving Platelet and, occasionally, Drug Substitution.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Matthew J. Price;Peter B. Berger;Paul S. Teirstein;Jean-François Tanguay.
Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention
Matthew J. Price;Peter B. Berger;Paul S. Teirstein;Dominick J. Angiolillo.
Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate
Laurent Bonello;Udaya S. Tantry;Rossella Marcucci;Ruediger Blindt.
Journal of the American College of Cardiology (2010)
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
Stephen D. Wiviott;Dietmar Trenk;Andrew L. Frelinger;Michelle O’Donoghue.
Variability in Individual Responsiveness to Clopidogrel: Clinical Implications, Management, and Future Perspectives
Dominick J. Angiolillo;Antonio Fernandez-Ortiz;Esther Bernardo;Fernando Alfonso.
Journal of the American College of Cardiology (2007)
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38
Stephen D. Wiviott;Eugene Braunwald;Dominick J. Angiolillo;Simha Meisel.
Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding
Udaya S. Tantry;Laurent Bonello;Daniel Aradi;Matthew J. Price.
Journal of the American College of Cardiology (2013)
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
Deepak L. Bhatt;Gregg W. Stone;Kenneth W. Mahaffey;C. Michael Gibson.
The New England Journal of Medicine (2013)
A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
Dietmar Trenk;Gregg W. Stone;Meinrad Gawaz;Adnan Kastrati.
Journal of the American College of Cardiology (2012)
Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies.
Raúl Moreno;Cristina Fernández;Rosana Hernández;Fernando Alfonso.
Journal of the American College of Cardiology (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: